Heart Failure – Geographic Focus: China – China In-Depth – Heart Failure

Heart failure remains a significant public health challenge in China, driven by urbanization, an aging population, and sedentary lifestyles. The treatment of acute heart failure (AHF) still largely depends on affordable generic medications such as diuretics and ACE inhibitors, but the treatment of chronic heart failure (CHF) is advancing with the growing use of newly approved therapies, particularly SGLT2 inhibitors (e.g., AstraZeneca’s Forxiga, Eli Lilly’s Jardiance) and ARNIs (e.g., Novartis’s Entresto). These treatments, supported by updated Chinese guidelines that align with global standards, are expected to drive substantial market growth through 2034, especially for heart failure with reduced ejection fraction (HFrEF). Nevertheless, significant unmet needs remain, especially in the treatment of heart failure with preserved ejection fraction (HFpEF). These patients have limited treatment options beyond symptom management and SGLT2 inhibitors. This gap, along with the limitations of current therapies in treating advanced stages of heart failure, presents a crucial opportunity for drug developers. Emerging treatments such as Eli Lilly’s tirzepatide and Bayer’s finerenone have the potential to partially address these needs over the next 10 years.

QUESTIONS ANSWERED

• How large are the treatable AHF, HFrEF, and HFpEF populations in China, and how will diagnosis rates change over time?
• What are interviewed experts’ insights into current treatments? Which clinical needs remain unfulfilled?
• What are the market access considerations for key therapies for heart failure in China? What sales / uptake could they secure?
• What are the drivers and constraints of the Chinese heart failure therapy market, and how will the market evolve through 2034?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape
• Gauge the commercial outlook and impact of key market events.

Release Date

July 2025

Geographies

China

Primary Research

Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 cardiologists in China

Epidemiology

Diagnosed prevalence of acute and chronic heart failure in urban versus rural China; clinically relevant and market-relevant drug-treatable populations

Forecast

10-year, annualized, drug-level sales and patient share of key heart failure therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions

Drug treatments

Coverage of key current and late-phase emerging therapies

Custom drug modeler

Integrated tool to input customized forecast assumptions (e.g., launch date, price)